Clene, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US1856341029
USD
6.29
-2.97 (-32.07%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

738.41 k

Shareholding (Mar 2025)

FII

0.19%

Held by 6 FIIs

DII

95.66%

Held by 3 DIIs

Promoter

1.59%

How big is Clene, Inc.?

22-Jun-2025

As of Jun 18, Clene, Inc. has a market capitalization of 38.00 million, with net sales of 0.35 million and a net profit of -29.08 million over the last four quarters. As of Dec 24, shareholder's funds are at -8.86 million, and total assets are 27.34 million.

As of Jun 18, Clene, Inc. has a market capitalization of 38.00 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 0.35 million, while the sum of Net Profit for the same period is -29.08 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at -8.86 million and Total Assets at 27.34 million.

Read More

What does Clene, Inc. do?

22-Jun-2025

Clene, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $0 million and a net loss of $1 million as of March 2025, with a market cap of $38 million. Key metrics include a negative P/E ratio and a return on equity of 618.92%.

Overview:<BR>Clene, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 38.00 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.45 <BR>Return on Equity: 618.92% <BR>Price to Book: -7.64<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Read More

Is Clene, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, Clene, Inc. has a bullish technical trend, supported by positive indicators like the weekly MACD, Bollinger Bands, and strong performance, outperforming the S&P 500 with a 49.06% return over the past month.

As of 2 September 2025, the technical trend for Clene, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supported by bullish signals from the Bollinger Bands and On-Balance Volume (OBV). Daily moving averages also indicate a bullish stance. The monthly MACD and KST are mildly bullish, while the Dow Theory shows a mildly bullish trend. <BR><BR>In terms of performance, Clene has outperformed the S&P 500 significantly over the past month with a return of 49.06% compared to the S&P's 2.33%, and it has also shown a positive return of 25.90% over the past year versus the S&P's 17.14%. Overall, the current technical stance is bullish with strong indicators supporting this view.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 66 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.15

stock-summary
Return on Equity

337.50%

stock-summary
Price to Book

-7.75

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-7 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
12.52%
0%
12.52%
6 Months
60.46%
0%
60.46%
1 Year
58.84%
0%
58.84%
2 Years
-27.53%
0%
-27.53%
3 Years
487.85%
0%
487.85%
4 Years
-94.07%
0%
-94.07%
5 Years
-97.19%
0%
-97.19%

Clene, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
4.06%
EBIT Growth (5y)
-231.07%
EBIT to Interest (avg)
-19.15
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.45
Sales to Capital Employed (avg)
0.02
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
27.26%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-7.68
EV to EBIT
-1.62
EV to EBITDA
-1.72
EV to Capital Employed
20.49
EV to Sales
45.36
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1261.83%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (2.56%)

Foreign Institutions

Held by 6 Foreign Institutions (0.19%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -100.00% vs -66.67% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -8.82% vs 72.91% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.50",
          "val2": "-7.00",
          "chgp": "21.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "1.30",
          "chgp": "-46.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.90",
          "val2": "1.60",
          "chgp": "-156.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.40",
          "val2": "-6.80",
          "chgp": "-8.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-217,185.20%",
          "val2": "-81,219.80%",
          "chgp": "-13,596.54%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -57.14% vs 40.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 20.40% vs -65.55% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.30",
          "val2": "0.70",
          "chgp": "-57.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-31.40",
          "val2": "-38.80",
          "chgp": "19.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.10",
          "val2": "4.60",
          "chgp": "-10.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.10",
          "val2": "-5.80",
          "chgp": "46.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-39.40",
          "val2": "-49.50",
          "chgp": "20.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-96,763.20%",
          "val2": "-61,987.80%",
          "chgp": "-3,477.54%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.10
-100.00%
Operating Profit (PBDIT) excl Other Income
-5.50
-7.00
21.43%
Interest
0.70
1.30
-46.15%
Exceptional Items
-0.90
1.60
-156.25%
Consolidate Net Profit
-7.40
-6.80
-8.82%
Operating Profit Margin (Excl OI)
-217,185.20%
-81,219.80%
-13,596.54%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is -100.00% vs -66.67% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -8.82% vs 72.91% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.30
0.70
-57.14%
Operating Profit (PBDIT) excl Other Income
-31.40
-38.80
19.07%
Interest
4.10
4.60
-10.87%
Exceptional Items
-3.10
-5.80
46.55%
Consolidate Net Profit
-39.40
-49.50
20.40%
Operating Profit Margin (Excl OI)
-96,763.20%
-61,987.80%
-3,477.54%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -57.14% vs 40.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 20.40% vs -65.55% in Dec 2023

stock-summaryCompany CV
About Clene, Inc. stock-summary
stock-summary
Clene, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available